Avid Bioservices, Inc.2024财年实现净利润-1.41亿美元，同比减少54540.15%

自选股智能写手07-04

7月4日，Avid Bioservices, Inc.（CDMO.US）公布财报，公告显示公司2024财年净利润为-1.41亿美元，同比减少54540.15%；其中营业收入为1.40亿美元，同比减少6.04%，每股基本收益为-2.23美元。从资产负债表来看，Avid Bioservices, Inc.（CDMO.US）总负债2.76亿美元，其中短期债务1.35百万美元，资产负债比为1.23，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2448455326?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-04 06:02","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2448455326","market":"us","top_or_hot":-1,"title":"Avid Bioservices, Inc.2024财年实现净利润-1.41亿美元，同比减少54540.15%","media":"自选股智能写手","content":"<div>\n<p>7月4日，Avid Bioservices, Inc.（CDMO.US）公布财报，公告显示公司2024财年净利润为-1.41亿美元，同比减少54540.15%；其中营业收入为1.40亿美元，同比减少6.04%，每股基本收益为-2.23美元。从资产负债表来看，Avid Bioservices, Inc.（CDMO.US）总负债2.76亿美元，其中短期债务1.35百万美元，资产负债比为1.23，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407040602379570b276&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avid Bioservices, Inc.2024财年实现净利润-1.41亿美元，同比减少54540.15%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvid Bioservices, Inc.2024财年实现净利润-1.41亿美元，同比减少54540.15%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-04 06:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407040602379570b276&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月4日，Avid Bioservices, Inc.（CDMO.US）公布财报，公告显示公司2024财年净利润为-1.41亿美元，同比减少54540.15%；其中营业收入为1.40亿美元，同比减少6.04%，每股基本收益为-2.23美元。从资产负债表来看，Avid Bioservices, Inc.（CDMO.US）总负债2.76亿美元，其中短期债务1.35百万美元，资产负债比为1.23，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407040602379570b276&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDMO","symbol_name":"Avid Bioservices, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407040602379570b276&s=b","article_id":"2448455326","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407040602379570b276&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2448455326","pubTimestamp":1720044147,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"7月4日，Avid Bioservices, Inc.公布财报，公告显示公司2024财年净利润为-1.41亿美元，同比减少54540.15%；其中营业收入为1.40亿美元，同比减少6.04%，每股基本收益为-2.23美元。从资产负债表来看，Avid Bioservices, Inc.总负债2.76亿美元，其中短期债务1.35百万美元，资产负债比为1.23，流动比率为0.02。机构评级：截至2024年7月4日，当前有4家机构对Avid Bioservices, Inc.目标价做出预测，其中目标均价为12.50美元，其中最低目标价为8.00美元，最高目标价为16.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"CDMO":"Avid Bioservices, Inc.","CDMOP":"Avid Bioservices, Inc. 10.50% Series E Convertible Preferred"},"translate_title":"Avid Bioservices, Inc. achieved net profit of-$141 million in fiscal 2024, a year-on-year decrease of 54540.15%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDMO":1,"CDMOP":1},"content_text":"7月4日，Avid Bioservices, Inc.（CDMO.US）公布财报，公告显示公司2024财年净利润为-1.41亿美元，同比减少54540.15%；其中营业收入为1.40亿美元，同比减少6.04%，每股基本收益为-2.23美元。从资产负债表来看，Avid Bioservices, Inc.（CDMO.US）总负债2.76亿美元，其中短期债务1.35百万美元，资产负债比为1.23，流动比率为0.02。机构评级：截至2024年7月4日，当前有4家机构对Avid Bioservices, Inc.目标价做出预测，其中目标均价为12.50美元，其中最低目标价为8.00美元，最高目标价为16.00美元。公司简介：Avid Bioservices Inc是一家临床阶段的生物制药公司，专注于从哺乳动物细胞培养物中提取的生物制药产品的开发和现行良好生产规范(CGMP)。 公司为生物技术和生物制药行业提供全面的工艺开发和高质量的CGMP临床和商业制造服务。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2448455326"}